Universe Pharmaceuticals INC (UPC) — Institutional Holders, Q2 2026
4 institutional investment managers reported a UPC position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $125.5K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
UPC in Q2 2026: what funds did
Funds that filed a 13F for both Q4 2025 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
New positions
3
Added to
1
Trimmed
0
Sold out
0
Biggest buyers
- UBS Group AGAdded · +13,421 sh+$81.9K
- OSAICNew · +6,172 sh+$37.6K
- Caitong International Asset Management , LtdNew · +12 sh+$73.00
Biggest sellers
None this quarter.
UPC 13F holders ranked 1–4 of 4
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q4 2025 |
|---|---|---|---|---|---|
| 1 | UBS Group AG#1 · 14,367 sh | 14,367 | $87.6K | 0.00% | +1418.7% |
| 2 | OSAIC#2 · 6,172 sh | 6,172 | $37.6K | 0.00% | New |
| 3 | HRT FINANCIAL#3 · 16,902 sh | 16,902 | $103.00 | 0.00% | New |
| 4 | Caitong International Asset Management , Ltd#4 · 12 sh | 12 | $73.00 | 0.00% | New |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q4 2025 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.